Stock of the Day
December 15, 2021
Insmed (INSM)
$73.28
+$0.54 (+0.7%)
Market Cap:
$13.37B
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
← Previous Stock of the Day
Next Stock of the Day →
Recent News
Martina M.D. Flammer Sells 1,686 Shares of Insmed Incorporated (NASDAQ:INSM) Stock
(insidertrades.com)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(prnewswire.com)